Skip to main content

Table 3 Endocrinological investigation: CRH/GRF/TRH/LHRH stimulation test in January 2018 (day 7 after admission)

From: Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature

  Time (min)
0 15 30 60 90 120
Adrenocorticotropic hormone (pg/ml) 2.1 3.5 4.0 3.4 2.9 2.2
Cortisol (μg/dl) < 0.2 < 0.2 < 0.2 < 0.2 < 0.2 < 0.2
Thyroid-stimulating hormone (μIU/ml) 5.47 22.86 33.95 28.66 23.64 17.65
Growth hormone (ng/ml) 7.67 19.96 34.68 38.76 37.53 21.17
Prolactin (ng/ml) 22.6 75.6 94.4 84.6 61.2 44.6
Luteinizing hormone (mIU/ml) 10.4 21.8 30.9 45.3 47.9 43.1
Follicle-stimulating hormone (mIU/ml) 32.8 36.2 33.6 36.6 45.6 45.5
  1. The following synthetic hypothalamic hormones were intravenously administered in the morning (9 a.m.): human corticotropin-releasing hormone (CRH; 100 μg), growth hormone-releasing factor (GRF; 100 μg), thyrotropin-releasing hormone (TRH; 500 μg), and luteinizing hormone-releasing hormone (LHRH; 100 μg)
  2. The hormone replacement therapy with oral levothyroxine (50 μg/day) for primary hypothyroidism was discontinued on day 2 after admission, and the patient’s serum levels of free thyroxine (1.26 ng/dl) and free triiodothyronine (2.77 pg/ml) were measured just before the drug administration